Guangdong Biolight Meditech Co., Ltd.

TEL AVIV, Israel , June 12, 2023 /PRNewswire/ -- BioLight a publicly traded company on the Tel Aviv Stock Exchange (TASE: BOLT), specializing in investments in biomed companies focusing on eye diseases, announced that its subsidiary, Diagnostear has entered into a binding LOI for a merger agreement with a Canadian corporation that is expected to list its shares on the Canadian Securities Exchange (CSE). Following the completion of the merger, Diagnostear is set to commence trading in Canada with an estimated value of US$ 33.5 million. BioLight will hold approximately 50% of the shares of the merged traded company, with the initial value of shares held by BioLIght being approximately US$ 16.8 million. As part of the agreement and a prerequisite for its closing, Diagnostear will raise approximately US$ 1 million, while the Canadian corporation will raise approximately US$ 2.5 million. Once the transaction is completed, and after all expenses related to the transaction and trading registration for the Canadian corporation have been paid, the merged company is expected to have a minimum cash balance of US$ 3 million. Diagnostear, of which Biolight currently holds 77% ownership, specializes in the development of eye tests based on tear fluid analysis. The funds raised from the aforementioned capital raises are designated to support the business plan of the merged company which includes advancing Diagnostear's dry eye detection product and the development of a new red-eye detection product. The completion of the transaction is subject to the aforementioned capital raisings and obtaining various customary necessary approvals. Yaacov Michlin, CEO of BioLight and Chairman of the Board of Directors of Diagnostear stated: "The merger and capital raise are expected to support Diagnostear in achieving its business objectives to commercialize the product for dry eye and complete the development of the red eye detection product. Both are parts of the company's strategy to become a global leader in diagnosing front-of-the-eye diseases through tear analysis in clinics. The registration for trading in Canada is expected to allow Diagnostear to increase awareness of its activities and effectively promote its plans." For forward looking statement, please see BioLight's report to the Tel Aviv Stock Exchange dated June 5 2023. For further information please contact: Yaacov Michlin CEO BioLight Life Sciences, Ltd. [email protected] SOURCE BioLight Life Sciences Ltd.

TEL AVIV, Israel, May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes components of the tear film, an outer eye surface fluid layer. The Technology was licensed from Harvard University and will be utilized to analyze tear samples by one of the inventors, Prof. Yifat Merbl, of the Weizmann Institute of Science. The study will be conducted at the Tel Aviv Medical Center and led by Prof. Anat Loewenstein, Chair of the Ophthalmology department. "Retinal disease affects the vision of hundreds of millions of people worldwide. Early detection and treatment in the preliminary stages of retinal eye disease can prevent vision loss for a significant number of people. Finding an effective and simple tool for diagnosing during the early stages of the disease's development is a game changer. This is the objective of the experiment and research, endeavoring to detect retinal disease through human tear sampling," stated Yaacov Michlin, CEO BioLight. About BioLight Life Sciences Ltd. BioLight manages and invests in companies with a primary focus on bringing vital products to the market in the field of ocular disease and novel treatments in Ophthalmology. About Alexion, AstraZeneca Rare Disease Alexion, AstraZeneca Rare Disease is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Forward-looking statement: The information, details, and BioLight's estimations contained in this report about the collaboration, trial, and research potential, commencement date of the study and its, execution methods, the results of the study, the collaboration prospects following it, and the approvals required in connection with the aforementioned are "forward-looking information" as defined in the Israeli Securities Law, 1968 which involves high uncertainty and is based, among other things, on third parties and on various variables over which the BioLight does not necessarily have control, and as a result, it is possible that the aforementioned information, details, and estimates, in practice, will not be realized and/or will not be fully realized and/or will materialize in a way that is fundamentally different from the initial estimations or observations. Contact: Yaacov Michlin +972509930707 yaacov@bio-light.co.il Photo - Company Codes: NASDAQ-NMS:BOLT, TelAviv:BOLT

DUBLIN--( BUSINESS WIRE )--The "Renal Dialysis Equipment: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed exposure to the renal dialysis equipment market. This report highlights the current and future market potential of renal dialysis equipment along with a detailed analysis of the drivers and challenges in the market. The report also covers market projections through 2027 and market rank for key market players. It also covers the competitive environment and regulatory scenario. The report details renal dialysis equipment market share based on product, application, and end user. The market is segmented by product into dialysis equipment, dialysate and other solutions, and dialysis accessories. The market by application is categorized as hemodialysis, peritoneal dialysis and CRRT (continuous renal replacement therapy). By end user the market is segmented into medical center dialysis and in-home dialysis. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also examines the impact of the COVID-19 pandemic on this market. By geographical region, the market has been arranged into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes a breakdown for the U.S. and Canada; Europe includes a breakdown for Germany, the U.K., Italy, France, Spain, and the Rest of Europe; Asia-Pacific includes a breakdown for China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2019 and 2020 as the historic year, 2021 as the base year, and forecasts through 2027. Report Includes 35 data tables and 33 additional tables Detailed overview and an up-to-date analysis of the global market for renal dialysis equipment and technologies Analyses of the global market trends, with historic market revenue (sales figures) for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027 Understanding of the current and future market potential for renal dialysis equipment, emerging technologies, and areas of focus to forecast this market into various segments and sub-segments Estimation of the actual market size and revenue forecast for global renal dialysis equipment market in USD million values, and corresponding market share analysis based on product, application, end user, and region Discussion of the major market dynamics of the renal dialysis products and end user segments, recent industry structure, technology advancements, and regulatory updates within the marketplace Coverage of the technological, economic, and business considerations of the renal dialysis industry, with analyses and growth forecasts through 2027 Country specific data and market value analysis for the U.S., Canada, Germany, Italy, Spain, U.K., France, Japan, China and India, among others Review of the key patents granted on renal dialysis across each major category Identification of the major stakeholders and analysis of the company competitive landscape based on their recent market developments, financial performance, and segmental revenues Descriptive company profiles of the leading global players, including Allmed Medical GmbH, B. Braun Melsungen AG, Baxter International Inc., Fresenius Medical Care, Medtronic Plc, Nipro Medical Corp., Rockwell Medical Inc., and Toray Industries Inc. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background 3.1 Definitions of Related Terms 3.2 Introduction 3.3 Introduction to the Kidney and Its Function 3.4 Understanding Renal Failure 3.5 Types of Kidney Failure 3.6 Treatment of Kidney Failure 3.7 Epidemiology 3.8 Renal Dialysis 3.9 Principles of Renal Dialysis 3.10 History of Renal Dialysis 3.11 Function of Renal Dialysis 3.12 Types of Renal Dialysis 3.13 Continuous Renal Replacement Therapy (Crrt) Chapter 4 Market Breakdown by Product Chapter 5 Market Breakdown by End-user Chapter 6 Market Breakdown by Application Chapter 7 Market Breakdown by Region Chapter 8 Competitive Landscape 8.1 Market Share Analysis 8.1.1 Recent Developments of Key Market Players Chapter 9 Patent Review 9.1 Patents, by Year 9.2 Patents, by Top Applicants 9.3 Patents, by Top Owners 9.4 Patents, by Jurisdiction Chapter 10 Analysis of Market Opportunities 10.1 Factors Affecting the Renal Dialysis Market 10.1.1 Drivers of the Renal Dialysis Market 10.1.2 Current Challenges for the Renal Dialysis Market Chapter 11 Impact of the Covid-19 Pandemic 11.1 Impact of Covid-19 on the Renal Dialysis Equipment Market Chapter 12 Emerging Technologies in the Market 12.1 Emerging Technologies in the Renal Dialysis Equipment Market 12.1.1 Living Donor Registry 12.1.2 Connected Health and Remote Sensors 12.1.3 Transitional Care Units 12.1.4 Removing Blood Thinners from Dialysis 12.1.5 Improved Fluid Management Chapter 13 Company Profiles Allmed Medical GmbH Asahi Kasei Corp. B. Braun Melsungen AG Baxter International Inc. Dialife S.A. Esco Medicon Farmasol Fresenius Medical Care Guangdong Biolight Meditech Co. Ltd. Hemoclean Co. Ltd. Landwind Industry Co. Ltd. Medica Group Medivators Inc. Medtronic plc Nikkiso Co. Ltd. Nipro Outset Medical Inc. Rockwell Medical U.S. Inc. Sws Hemodialysis Care Co. Ltd. Toray Industries Inc. Chapter 14 Appendix: Abbreviations For more information about this report visit https://www.researchandmarkets.com/r/juxdff About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.